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Abstract
Classical Hodgkin lymphoma (CHL) is a B-cell lymphoproliferative disorder with a relatively good prognosis. A small
but significant percentage of patients, however, will respond poorly to therapy. A recent gene expression profiling
study has identified a macrophage signature which has been correlated with primary treatment failure, and
immunohistochemical tissue microarray for CD68 was shown to reflect the gene signature as a potentially clinically
useful marker to predict adverse prognosis.
We examined 44 cases of CHL, mostly nodular sclerosis subtype, in which the immunohistochemical stains for the
histiocytic markers CD68 and CD163 were performed. The staining intensity was graded for each stain (< 5, 5-25,
and > 25 percent of cells positive in the Hodgkin cell (HC) rich nodules) and background staining characteristics
were recorded.
CD163 staining was lower than CD68 in HC rich nodules, with lower background staining (p 0.03). There was no
significant difference between either CD68 or CD163 and disease recurrence in a subset (N = 41) of cases.
In conclusion, we demonstrate that CD163 staining is lower than CD68, with less non-specific staining of
background inflammatory cells and Hodgkin cells, therefore is a better marker for tumor associated macrophages.
However, we did not identify a correlation between staining for CD68 or CD163 and recurrence of disease.
Virtual slides: The virtual slide(s) for this article can be found here:
http://www.diagnosticpathology.diagnomx.eu/vs/1460518258831620
Introduction
Classical Hodgkin lymphoma is a B cell lymphoma with a
relatively good prognosis. However, approximately 20% of
patients will be refractory to primary treatment or relapse
after remission [1]. The cellular microenvironment has
been extensively studied and plays an important part in
the pathogenesis of Hodgkin lymphoma. Tissue microar-
ray studies have proven useful in the study of Hodgkin
lymphoma [2-4], in which the neoplastic cells are relatively
few compared with the highly cellular inflammatory and
stromal background. Several studies have used gene
expression profiles to study the microenvironment in clas-
sical Hodgkin lymphoma [5-7]
Tumor associated macrophages have been associated
with disease status in non-hematologic malignancies [8].
A macrophage gene profile in classical Hodgkin lym-
phoma was identified in two studies, and was associated
with unfavorable outcome [2,6]. The former study also
used tissue microarray immunohistochemical staining for
the monocyte/macrophage marker, CD68 on an indepen-
dent cohort of patients and found high numbers of
tumor associated macrophages were associated with
shortened progression free survival and increased likeli-
hood of relapse post autologous stem cell transplant. In
addition, this study found a low CD68 score was asso-
ciated with 100% disease-specific survival in patients with
limited stage disease (stage I and IIa). Assuming these
immunohistochemical findings can be reproduced, this
may indicate the necessity of a practical approach to enu-
merating macrophages in the everyday practice of
pathology.
CD68 (Kp-1) is a glycoprotein used as a monocyte/
macrophage marker but is relatively non-specific. It also
can stain myeloid cells, dendritic cells, fibroblasts, Langer-
hans cells and others. CD163 is a member of the scavenger
receptor family and is specific for the monocyte/macro-
phage lineage [9,10]. We tested 44 cases of classical Hodg-
kin lymphoma for antibodies to both CD68 and CD163 to
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enumerate tumor associated macrophages in classical
Hodgkin lymphoma.
In addition, we concurrently performed chart review
on a subset of 41 patients to compare level of staining
with disease recurrence following treatment.
Materials and methods
We searched the pathology database at our institution for
cases of classical Hodgkin lymphoma diagnosed between
January 2000 and August 2010. Cases were selected
based on available blocks with adequate tissue (~1 cm
2).
Adequate diagnostic material was found for 44 cases,
most of which were nodular sclerosis subtype (Table 1).
This study was approved by the institutional review
board at the NYU School of Medicine.
We performed immunohistochemical stains using
CD68, Clone KP-1, and CD163, Clone MRQ-26, (Ven-
tana Medical Systems, Tucson AZ) on representative for-
malin fixed, paraffin embedded tissue blocks from each
case. In brief, sections were deparaffinized in xylene (3
changes), rehydrated through graded alcohols (3 changes
100% ethanol, 3 changes 95% ethanol) and rinsed in dis-
tilled water. Heat induced epitope retrieval was per-
formed in a 1200-Watt microwave oven at 90% power
using 0.01 M Citrate buffer pH 6.0 for 5 and 20 minutes
respectively. Sections were allowed to cool for 30 minutes
and then rinsed in distilled water. Antibody incubations
and detection were carried out at 37°C on a NEXes
instrument (Ventana Medical Systems Tucson, AZ) using
Ventana’s reagent buffer and detection kits unless other-
wise noted. Endogenous peroxidase activity was blocked
with hydrogen peroxide. Both antibodies were applied
neat and incubated for 30 minutes. Primary antibody was
detected using a biotinylated goat anti-mouse followed
by application of streptavidin-horseradish-peroxidase
conjugate. The complex was visualized with 3,3 diamino-
benzidene and enhanced with copper sulfate. Slides were
washed in distilled water, counterstained with hematoxy-
lin, dehydrated and mounted with permanent media.
Appropriate positive and negative controls were included
with the study sections.
Stains were compared with corresponding H&E stained
sections. The level of CD68 and CD163 staining was
recorded by two independent investigators (JH, QR) and
graded with respect to the relative percentage of tumor
associated macrophages in HRS (Hodgkin Reed-Sternberg
cells) rich areas. The few discrepant cases were reviewed
together until agreement was reached. The percentage was
recorded and graded as: 1 if less than 5%, 2 if 5-25%, and 3
if greater than 25% of the total cells present in HRS rich
nodules were positive for CD68 or CD163.
Statistical analysis was performed using a Student’s
t-test to compare the staining between CD68 and CD163.
Independent chart review was simultaneously per-
formed on 41 cases to determine the clinical outcome
since the original diagnosis. Disease stage, time to dis-
ease recurrence, and treatment regimen were recorded,
along with lines of treatment (chemotherapy versus
autologous stem cell transplant, etc). Disease recurrence
occurred in 9 patients, 4 with limited stage disease
(stage I or IIa).
For comparison study, outcome was good if disease free
and poor if disease recurred. Both CD68 and CD163 were
compared to both outcome groups using a Fisher Exact
Probability Test with Freeman-Halton 2 × 3 extension to
compare the groups of disease free and disease recurrence
with the three staining levels.
Results
After analyzing 44 cases of classical Hodgkin lymphoma,
CD163 showed lower staining levels than CD68 in HRS
rich areas. (p 0.01)(Figure 1a). CD163 staining pattern
showed a more clean background than CD68, with less
non-specific staining of Hodgkin Reed-Sternberg cells and
other inflammatory elements (Figure 1b). CD68 showed
more variability in staining within the same tissue, with
grade 3 staining in some nodules and grade 1 staining in
adjacent HRS rich nodules (Figure 1c). CD163 staining
pattern was characteristically higher in the sclerotic bands
as compared with the HRS rich nodules (Figure 2). CD163
showed more consistent staining, with only one case
showing more CD163 than CD68. Two cases showed sig-
nificantly more staining for CD68 than with CD163 (grade
3 compared to grade 1) with all other discrepant cases
showing only a one grade difference. CD68 stained HRS
cells more frequently than did CD163.
Analysis of the subset of 41 patients revealed no statisti-
cal difference among the three grading groups for CD68
or CD163 and disease recurrence (p 0.66 and p 0.70 for
CD68 and CD163 respectively). In the two cases with sig-
nificantly more CD68 than CD163, and the one case with
more CD163 than CD68, there was no disease recurrence.
Discussion
Tumor associated macrophages play an important role in
classical Hodgkin lymphoma, with reported gene signa-
tures associated with adverse outcome following primary
treatment [2]. We used immunohistochemical staining for
the macrophage/monocyte markers CD68 and CD163 to
directly compare the staining characteristics in 44 cases of
classical Hodgkin lymphoma. While CD68 is a marker for
cells of the monocyte/macrophage lineage, it is relatively
nonspecific, with reported staining in neoplasms such as
carcinoma, melanoma, angiosarcoma, lymphoma, and
schwannoma [10]. There is also nonspecific staining in
fibroblasts and inflammatory cells [9], a finding we
demonstrated in this study. CD163 has been shown to be
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lineage [10].
CD163 showed lower staining than CD68 in HRS rich
areas, with lower background staining and less staining of
HRS cells. In cases with extremely high levels of CD68
and CD163, we did find occasional HRS cells staining
for CD163, but in much fewer numbers than were stain-
ing for CD68. One study reported that CD163 may be
Table 1 Clinical information and analysis results
Demographics Clinical Characteristics Immunohistochemical Analysis
2
Patient Age Sex Stage Tumor size (cm)
1 CD68 CD163 p value
1 21 F IIA 6 2 1 0.01
2 73 M IIIB 3 2 1
3 37 M IIA 2 3 2
4 59 F IIA 4.3 3 3
5 42 F IIA 4 3 3
6 94 M IIA 2.2 3 1
7 20 F IIIA > 10 2 1
8 19 F IIA > 10 3 3
9 51 M IVA > 10 3 3
10 28 M IIA 2.5 2 1
11 33 F IVB 3 2 2
12 62 F IIB 2 2 2
13 15 F IIIA > 10 2 2
14 22 M IIA 2 1 1
15 23 F IIB > 10 1 1
16 33 M IA 2.8 2 2
17 48 M IB 3 2 2
18 17 F IVB 5 2 2
19 25 F IIB 17 1 1
20 52 M IVB 4 3 3
21 45 M IVB 11 2 1
22 20 M IIB 2 3 3
23 64 M IVB 5.5 1 1
24 23 M IIA 4 3 3
25 14 M IVB 9.4 2 2
26 14 F IVB 3 1 1
27 35 M IIA 1.8 2 1
28 54 M IIIB 4.9 2 1
29 40 M IV 2.2 3 1
30 21 F IA 10 3 3
31 34 F IA 6.3 2 2
32 17 F IVB 5.1 2 3
33 22 F IIB 7.5 2 2
34 66 F IIIA 1.7 2 2
35 26 F IVA 1.6 1 1
36 24 M IV 6.3 2 2
37 35 M IIA 1.5 3 3
38 23 F IIA 2.5 3 3
39 26 M IVB 2.3 2 2
40 18 F IIIA 6 1 2
41 49 M IA 9 2 2
42 70 F IVB 2.4 2 1
43 21 M IIA 3 1 1
44 38 M IA 4 3 3
1 The tumor size was calculated as the largest diameter of the largest involved LN
2 Score of 1 = 0-5%, 2 = 5-25%, and 3 = > 25% staining of total cells in HRS rich areas
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synovial tissues [9], suggesting that it may be underrepre-
sented in tumor associated macrophages. Although we
did show fewer cells staining for CD163 in the HRS rich
nodules, there were several cases with abundant CD163
staining, which does not support this finding.
Figure 1 Immunohistochemical Results, a: CD163 (right) showed lower staining levels than CD68 in HRS rich areas. b: CD163 (right)
staining pattern shows cleaner background than CD68, with less non-specific staining. c: CD68 showed more variability in staining within the
same tissue, with grade 3 staining (right) in some nodules and grade 1 staining (left) in adjacent HRS rich nodules.
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histologic sections. Immunohistochemical stains which
non-specifically highlight background cells and stromal
elements complicate the matter further. In addition, varia-
bility of staining from one area of the slide to the next can
make an accurate determination even more challenging.
Tissue microarray is a powerful tool but cannot comple-
tely address the variability of staining from one area of the
tissue to another, even in paired core analysis. Ideally, an
immunohistochemical stain can specifically highlight the
cells of interest, and enumeration can be accurately repro-
duced by multiple pathologists. In the case of classical
Hodgkin lymphoma, there is a myriad of inflammatory
and stromal elements surrounding the relatively few neo-
plastic cells, and high background staining can complicate
matters when using the non-specific immunostain CD68.
As most cases of classical Hodgkin lymphoma are nodular
sclerosis type, the HRS rich areas are usually confined to
the centers of the nodules, simplifying the evaluation of
immunohistochemical markers by limiting the grading to
those nodules. CD163 staining characteristically shows a
honeycomb pattern on low power, with relatively few cells
in the nodules staining and more cells in the surrounding
fibrotic stroma. We do acknowledge there is generally not
an ideal marker for the tissue identification of subsets of
macrophages, however, as compared with the commonly
used antibody to CD68 (KP-1), CD163 appears to be a bet-
ter marker for enumeration of tumor associated macro-
phages classical Hodgkin lymphoma.
Of note, we did not find a correlation between staining
level and disease recurrence in the subgroup of 41
patients. Of the 9 patients with disease recurrence, 4
patients had limited stage disease. One patient with recur-
rent disease had < 5% staining (grade 1) for both CD68
and CD163. Our findings support those of a recent study
by Azambuja, et al, which found no correlation between
the numbers of CD68 and CD163 positive cells and either
progression free survival or disease specific survival in 265
cases of uniformly treated classical Hodgkin lymphoma
[11]. Although they did not directly compare CD163 to
CD68 statistically, they noted that CD163 is an easier stain
to read as there is less background than CD68.
In conclusion, we determined that CD163 is a better
marker than CD68 for the enumeration of tumor asso-
ciated macrophages in the everyday practice of surgical
pathology. Our study, together with the larger study by
Azambuja, et al, shows evidence that there is no differ-
ence between histologically enumerated macrophages
and clinical outcome in cases of classical Hodgkin lym-
phoma. Together, these findings do not support the pre-
viously published findings of Steidl, et al [2]. Additional
work may be necessary to determine the validity of rou-
tine staining for tumor associated macrophages.
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